We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Rapid POC Test for Diagnosis of Preeclampsia Could Prevent Unnecessary Hospitalization

By LabMedica International staff writers
Posted on 16 May 2022

Preeclampsia is a pregnancy disorder that can have devastating effects on the health of the mother and the unborn baby. More...

Affecting 5-8% of all pregnancies, it is a rapidly progressive and potentially deadly condition. A correct diagnosis of the pregnancy disorder is currently time-consuming and, in many cases, inaccurate. Now, a fast and precise point-of-care test for preeclampsia is being developed that would provide diagnostic certainty and at the same time, save healthcare costs.

MOMM Diagnostics (Basel, Switzerland) is developing a rapid test for preeclampsia that would offer unprecedented sensitivity at the point-of-care. MOMM develops high-sensitivity rapid diagnostic tests. Immediate information during pregnancy check-ups will help doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs. The rapid test for preeclampsia will be based on the company’s technology that combines the commercial advantage of lateral flow immunoassays, with the sensitivity of ELISA, and reader simplicity similar to blood glucose meters.

Since pregnant women regularly go to medical check-ups, the test can be carried out at the gynecologist without the need to send blood samples to a specialized diagnostics lab. The rapid screening test for preeclampsia will also spare expectant mothers the long wait for lab results. This will save valuable time and enable treatment to be started quickly. By providing diagnostic certainty, the test would also eliminate the possibility of false positive results by conventional tests that can create unnecessary anxiety for pregnant women.

Related Links:
MOMM Diagnostics 


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.